Cite
HARVARD Citation
Kim, Y. et al. (2017). Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01). Cancer. 123 (11), pp. 1958-1964. [Online].